下调SCD1表达增敏RSL3诱导铁死亡抑制膀胱癌细胞生长

Abstract
Figure/Table
References
Related Citation (2)

Download: PDF (8334 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the effect and mechanism of SCD1 protein expression on the ability of ferroptosis activator RSL3 to induce ferroptosis in bladder cancer cells. Method T24 cells were treated with SCD1 small interfering RNA (siRNA), specific SCD1 inhibitor (A9) or combined with RSL3; The effects of inhibiting SCD1 expression or combining with RSL3 on cell proliferation and clonogenesis were detected by CCK-8 and clonogenesis assay; Malondialdehyde (MDA) and lipid peroxides (LPO) were determined to investigate the effect of down-regulated SCD1 on the ability of RSL3 to induce ferroptosis in bladder cancer cells T24; Finally, glutathione peroxidase 4(GPX4) expression was detected by western blot. Results Both siRNA silencing and A9 treatment decreased the proliferation and colony formation ability of bladder cancer cells. Compared with the single treatment group, The two SCD1 inhibition methods combined with RSL3 further increased the MDA and LPO content in the cells, and enhanced the degree of inhibition on the proliferation and clonal colony formation of bladder cancer cells. In addition, inhibition of SCD1 enhanced the inhibitory effect of RSL3 on GPX4 protein expression. Conclusion Down-regulation of SCD1 can inhibit the growth of bladder cancer cells by enhancing the inhibition of GPX4 protein expression by RSL3 and inducing ferroptosis.

Key words： bladder cancer ferroptosis SCD1 GPX4

Received: 21 September 2023

PACS:

R737.14

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	DENG Jun
	LIU Wen

Cite this article:

DENG Jun,LIU Wen. Down-regulating SCD1 expression sensitizes RSL3 induced ferroptosis and inhibited bladder cancer cell growth[J]. HuNan ShiFan DaXue XueBao(YiXueBan), 2023, 20(6): 49-54.

URL:

http://yxb.hunnu.edu.cn/EN/ OR http://yxb.hunnu.edu.cn/EN/Y2023/V20/I6/49

[1] VAN HOOGSTRATEN LMC, VRIELING A, VAN DER HEIJDEN AG, et al. Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice[J]. Nat Rev Clin Oncol, 2023, 20: 287-304.
[2] PENG M, XIAO D, BU Y, et al.Novel Combination Therapies for the Treatment of Bladder Cancer[J]. Front Oncol, 2020, 10: 539527.
[3] SZABADOS B, KOCKX M, ASSAF ZJ, et al.Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder[J]. Eur Urol, 2022, 82: 212-222.
[4] SIEFKER-RADTKE AO, NECCHI A, PARK SH, et al.Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study[J]. Lancet Oncol, 2022, 23: 248-258.
[5] KANG N, SON S, MIN S, et al.Stimuli-responsive ferroptosis for cancer therapy[J]. Chem Soc Rev, 2023, 52: 3955-3972.
[6] REN Y, MAO X, XU H, et al.Ferroptosis and EMT: key targets for combating cancer progression and therapy resistance[J]. Cell Mol Life Sci, 2023, 80: 263.
[7] SEN U, COLEMAN C, SEN T.Stearoyl coenzyme A desaturase-1: multitasker in cancer, metabolism, and ferroptosis[J]. Trends Cancer, 2023, 9: 480-489.
[8] MIN JY, KIM DH.Stearoyl-CoA Desaturase 1 as a Therapeutic Biomarker: Focusing on Cancer Stem Cells[J]. Int J Mol Sci, 2023, 2424(10) : 8951.
[9] WU T, WAN J, QU X, et al.Nodal promotes colorectal cancer survival and metastasis through regulating SCD1-mediated ferroptosis resistance[J]. Cell Death Dis, 2023, 14: 229.
[10] PRESLER M, WOJTCZYK-MIASKOWSKA A, SCHLICHTHOLZ B, et al.Increased expression of the gene encoding stearoyl-CoA desaturase 1 in human bladder cancer[J]. Mol Cell Biochem, 2018, 447: 217-224.
[11] CHEN Z, WANG W, ABDUL RAZAK SR, et al.Ferroptosis as a potential target for cancer therapy[J]. Cell Death Dis, 2023, 14: 460.
[12] ZHU X, LI S. Ferroptosis, Necroptosis,Pyroptosis in Gastrointestinal Cancers: The Chief Culprits of Tumor Progression and Drug Resistance[J]. Adv Sci (Weinh) , 2023, 10: e2300824.
[13] DENG J, PENG M, WANG Z, et al.Novel application of metformin combined with targeted drugs on anticancer treatment[J]. Cancer Sci, 2019, 110: 23-30.
[14] CHEN L, HAN X.Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future[J]. J Clin Invest, 2015, 125: 3384-3391.
[15] LINGEL H, BRUNNER-WEINZIERL MC.CTLA-4 (CD152) : A versatile receptor for immune-based therapy[J]. Semin Immunol, 2019, 42: 101298.
[16] PIAO C, CUI X, ZHAN B, et al.Inhibition of stearoyl CoA desaturase-1 activity suppresses tumour progression and improves prognosis in human bladder cancer[J]. J Cell Mol Med, 2019, 23: 2064-2076.
[17] ALJOHANI AM, SYED DN, NTAMBI JM.Insights into Stearoyl-CoA Desaturase-1 Regulation of Systemic Metabolism[J]. Trends Endocrinol Metab, 2017, 28: 831-842.
[18] CHEN H, QI Q, WU N, et al.Aspirin promotes RSL3-induced ferroptosis by suppressing mTOR/SREBP-1/SCD1-mediated lipogenesis in PIK3CA-mutatnt colorectal cancer[J]. Redox Biol, 2022, 55: 102426.
[19] MA MKF, LAU EYT, LEUNG DHW, et al.Stearoyl-CoA desaturase regulates sorafenib resistance via modulation of ER stress-induced differentiation[J]. J Hepatol, 2017, 67: 979-990.
[20] LIU Y, LIU X, WANG H, et al.Agrimonolide inhibits cancer progression and induces ferroptosis and apoptosis by targeting SCD1 in ovarian cancer cells[J]. Phytomedicine, 2022, 101: 154102.
[21] XUAN Y, WANG H, YUNG MM, et al.SCD1/FADS2 fatty acid desaturases equipoise lipid metabolic activity and redox-driven ferroptosis in ascites-derived ovarian cancer cells[J]. Theranostics, 2022, 12: 3534-3552.
[22] LI Z, ZHU Z, LIU Y, et al.Function and regulation of GPX4 in the development and progression of fibrotic disease[J]. J Cell Physiol, 2022, 237: 2808-2824.
[23] CHANG MT, TSAI LC, NAKAGAWA-GOTO K, et al.Phyto-sesquiterpene lactones DET and DETD-35 induce ferroptosis in vemurafenib sensitive and resistant melanoma via GPX4 inhibition and metabolic reprogramming[J]. Pharmacol Res, 2022, 178: 106148.